House Democrats Start Probe Into Multiple Sclerosis Drug Prices

House Democrats Start Probe Into Multiple Sclerosis Drug Prices


House Democrats have started what they called an "in-depth" investigation into the pricing of drugs for neurological condition multiple sclerosis, the latest attempt by U.S. politicians to pressure manufacturers to lower costs. Biogen Inc. , Sanofi, Novartis AG, Roche Holding AG, Bayer AG, Merck KGaA's EMD Serono unit and Teva Phamaceuticals Industries Ltd. -- received letters requesting information on pricing strategies from Elijah Cummings and Peter Welch, two representatives who sit on the House Committee on Oversight and Government Reform.



from Biotech News